CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
|Podcasts|March 25, 2021
Podcast: Contact lens wear is a healthy option for kids
Advertisement
New data shows that contact lens wear is a healthy option for kids as young as age 8. Jill Woods, MSc, MCOptom, FAAO, FBCLA, discusses research summarized in a recent
Advertisement
Related to this article
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin IL-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5